CD30: an important new target in hematologic malignancies

Abstract

CD30 is abundantly and selectively expressed on the surface of Hodgkin Reed-Sternberg cells, anaplastic large cell lymphomas (ALCLs), and other lymphoid malignancies as well as on several non-lymphoid malignancies including selected germ cell tumors. Expression of CD30 on normal cells is highly restricted, thereby allowing differential targeting of malignant cells. CD30, a member of the tumor necrosis factor (TNF)-receptor family has pleiotropic biologic functions, and antibodies targeting CD30 and other TNF family receptors can exhibit both agonistic and antagonistic signaling functions. Recently, antibody-drug conjugates targeting CD30, such as brentuximab vedotin, have shown striking activity in phase I and II trials, with manageable toxicity. This has defined an important emerging role for targeting of CD30 in the setting of Hodgkin lymphoma, ALCL, and possibly other CD30+ malignancies.

CD30 Expression vs. Serum Soluble CD30 (sCD30) Level: Role in Prognosis and Treatment of Acute Myeloid Leukaemia

“…Nadali et al stated that CD30 is also detected on non-lymphoid germ cells neoplasms, and can be found sometimes in mesenchymal tumors and nasopharyngeal carcinoma [21,22]. For serum sCD30 levels, high levels have been reported in different neoplasms (HL, ALCL, nasopharyngeal carcinoma, embryonal carcinoma of the testis) characterized by strong T-cell or B-cell activation [23]. In this study we reported that there was a significant correlation between both high CD30 expression and elevated sCD30 and WBCs count, BM blasts, adverse risk cytogenetics, FLT3/ITD mutation (That in contrast to Zheng W et al that found that CD30 expression did not associate with NPM1, FLT3 ITD, D835, or RAS mutation state [24].…”

Hodgkin's Lymphoma: From Tumor Microenvironment to Immunotherapeutic Approach - Body's Own Power Protection Challenges

“…CD30 is expressed abundantly on RS cells of HL, and in other numerous lymphoid malignancies of B-, T-, and natural killer (NK)-cell origin (Deutsch et al, 2011). Regarding its biological activity CD30 has pleiotropic biologic functions, being capable of promoting cell proliferation and survival as well as inducing antiproliferative responses and cell death.…”

“…Regarding its biological activity CD30 has pleiotropic biologic functions, being capable of promoting cell proliferation and survival as well as inducing antiproliferative responses and cell death. Final effects of CD30 activation seem largely dependent on the microenvironment context (Deutsch et al, 2011). Unconjugated anti-CD30 antibodies have been tested in phase I and II studies showing limited clinical activity (Kasamon & Ambinder, 2008).…”

Trial Watch: Monoclonal antibodies in cancer therapy

“…overexpressed by anaplastic large-cell and Hodgkin lymphoma. 38 Contrarily to previous CD30-targeting approaches, brentuximab vedotin was found to induce durable objective responses and resulted in tumor regression in most patients with relapsed or refractory CD30-positive lymphomas. 39 Today, brentuximab vedotin is being investigated in patients at high risk of residual Hodgkin lymphoma following stem cell transplant ( Table 3, NCT01100502).…”